MEDILINK THERAPEUTICS
MediLink Therapeutics has established its R&D center in Suzhou, China. The company focuses on developing next generation drug conjugates, and aims to serve the vast unmet medical needs in China, and create global value through conducting multicenter clinical trials and cross-border collaborations.
MEDILINK THERAPEUTICS
Industry:
Biotechnology Genetics Therapeutics
Founded:
2020-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Status:
Active
Total Funding:
120 M USD
Similar Organizations
Laekna Therapeutics
Laekna Therapeutics is a biotech company focusing on drug discovery and development.
Current Employees Featured
Founder
Investors List
Loyal Valley Capital
Loyal Valley Capital investment in Series B - Medilink Therapeutics
Legend Capital
Legend Capital investment in Series B - Medilink Therapeutics
Qiming Venture Partners
Qiming Venture Partners investment in Series B - Medilink Therapeutics
LYFE Capital
LYFE Capital investment in Series B - Medilink Therapeutics
Highlight Capital
Highlight Capital investment in Series B - Medilink Therapeutics
Loyal Valley Capital
Loyal Valley Capital investment in Series A - Medilink Therapeutics
Apricot Capital
Apricot Capital investment in Series A - Medilink Therapeutics
Qiming Venture Partners
Qiming Venture Partners investment in Series A - Medilink Therapeutics
More informations about "Medilink Therapeutics"
MediLink Therapeutics - LinkedIn
MediLink Therapeutics | 1,149 followers on LinkedIn. MediLink Therapeutics focuses on developing competitive drug conjugates internationally. With independent intellectual property rights ...See details»
MediLink Therapeutics 2025 Company Profile: Valuation, Funding ...
MediLink Therapeutics General Information Description. Developer of antibody-drug conjugates (ADC) based in China. The company focuses on providing patients with ADC therapeutics that …See details»
Medilink Therapeutics - Funding, Financials, Valuation & Investors
Medilink Therapeutics is a biotech company focusing on next-generation antibody-drug conjugate Research & development. New. Resources. Advanced Search. Start Free Trial . ... How much …See details»
Medilink Therapeutics
Jan 10, 2025 About MediLink MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing innovative conjugated drugs for global patients. MediLink …See details»
Medilink Therapeutics
Oct 8, 2024 About MediLink Therapeutics MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing conjugated drugs with global competitiveness. …See details»
Medilink Therapeutics
Oct 12, 2023 MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a …See details»
MediLink Therapeutics Entered into Worldwide Collaboration and …
ACADEMICIAN WORKSTATION LEADING SCIENTISTS CORE TEAM COLLABORATING SCIENTISTS AND ORGANIZATION OUR FOCUS PIPELINE IN-DEPTH LOOK SCIENTIFIC …See details»
MediLink Therapeutics Announces Strategic …
SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- MediLink Therapeutics ("MediLink"), announced today that it has entered into a strategic research collaboration and worldwide license agreement with ...See details»
MediLink Therapeutics Announces Worldwide …
Jan 2, 2024 About MediLink Therapeutics. MediLink Therapeutics founded in 2020, is a clinical stage biotech company focused on developing globally competitive conjugated drugs. MediLink has built a differentiated proprietary …See details»
Medilink Therapeutics - Contacts, Employees, Board Members, …
Medilink Therapeutics is a biotech company focusing on next-generation antibody-drug conjugate Research & development. New. ... Experience the new Crunchbase, powered by AI . …See details»
MediLink Therapeutics Announces Worldwide Collaboration and …
Jan 2, 2024 The Tumor Microenvironment Activable LINker-payload (TMALIN ®) is a novel ADC platform technology developed by MediLink Therapeutics with independent intellectual …See details»
MediLink Therapeutics Announces Strategic Collaboration And …
MediLink Therapeutics Announces Strategic Collaboration And Worldwide License Agreement With BioNTech To Develop Next-Gen Anti-Cancer ADCs ... BioNTech will provide MediLink …See details»
Medilink Therapeutics
Feb 2, 2025 YL217 has been developed by utilizing MediLink's Tumor Microenvironment Activable LINker-payload (TMALIN®) technology platform. The phase I trial for YL217 is in …See details»
Exploring the Latest c-MET ADC Deal by MediLink Therapeutics
Jan 2, 2024 About Medilink Therapeutics. Suzhou Medilink Therapeutics Ltd. is a relatively new biomedicine organization that has been actively involved in drug development since its …See details»
MediLink Therapeutics Announces Strategic Collaboration and
SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- MediLink Therapeutics (“MediLink”), announced today that it has entered into a strategic research collaboration and worldwide license …See details»
Medilink Therapeutics Raises $50 Million in Series A Financing To ...
Mar 1, 2021 Medilink Therapeutics was established in 2020 by a sophisticated team of industrial veterans. Dr. Xue has comprehensive experience in R&D, manufacture and business …See details»
BioNTech Nets MediLink ADC in Potential $1B Cancer Deal
Oct 12, 2023 China-headquartered MediLink Therapeutics has entered into a deal with BioNTech for development of a next-generation antibody-drug conjugate candidate (ADC) …See details»
Medilink Therapeutics
Dec 18, 2024 About MediLink MediLink Therapeutics, founded in 2020, is a clinical stage biotech company dedicated to developing innovative conjugated drugs for global patients. …See details»
Beam Therapeutics Announces Clearance of Investigational New …
1 day ago CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines …See details»
Medilink Therapeutics
3 days ago March 25, 2025- MediLink Therapeutics (“MediLink”), a clinical-stage biotechnology company, announces the presentation of preclinical data for two innovative ADC programs …See details»